SOLIGENIX INC.NEW DL-,001
SOLIGENIX INC.NEW DL-,001
Share · US8342235053 · SNGX · A3D506 (XNCM)
Overview Financial Indicators
1,64 EUR
0,86 % 0,01 EUR
Frankfurt (XNAS) · Current prices and charts at MoneyPeak
10.06.2025 19:59

Current Prices from SOLIGENIX INC.NEW DL-,001

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
SNGX
USD
10.06.2025 19:59
1,87 USD
1,85 USD
+0,86 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % -1,42 % -6,74 % -21,69 % -50,37 % -48,77 % -99,63 %

Company Profile for SOLIGENIX INC.NEW DL-,001 Share

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Company Data

Name SOLIGENIX INC.NEW DL-,001
Company Soligenix, Inc.
Symbol SNGX
Website https://www.soligenix.com
Primary Exchange XNCM Frankfurt
WKN A3D506
ISIN US8342235053
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Christopher J. Schaber Ph.D.
Country United States of America
Currency EUR
Employees 0,0 T
Address 29 Emmons Drive, 08540 Princeton
IPO Date 1994-04-04

ID Changes

Date From To
30.09.2009 DORB SNGX

Ticker Symbols

Name Symbol
NASDAQ SNGX

More Shares

Investors who SOLIGENIX INC.NEW DL-,001 hold also have the following shares in their portfolio:
LAND NRW MTN.LSA R.1569
LAND NRW MTN.LSA R.1569 Bond
SOUTHERN PACIFIC SECURITIES 05-1 PLC A1C MTG BCKD FRN 10/06/25 GBP(REGS)
SOUTHERN PACIFIC SECURITIES 05-1 PLC A1C MTG BCKD FRN 10/06/25 GBP(REGS) Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025